$8.48
Live
Insights on Bausch Health Companies Inc
Revenue is up for the last 4 quarters, 1.94B → 2.40B (in $), with an average increase of 6.8% per quarter
Netprofit is up for the last 2 quarters, -378.0M → 395.0M (in $), with an average increase of 195.7% per quarter
In the last 1 year, Neurocrine Biosciences Inc. has given 35.3% return, outperforming this stock by 22.5%
In the last 3 years, Neurocrine Biosciences Inc. has given 44.8% return, outperforming this stock by 116.0%
0.35%
Downside
Day's Volatility :1.63%
Upside
1.28%
34.32%
Downside
52 Weeks Volatility :51.4%
Upside
26.0%
Period | Bausch Health Companies Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 6.09% | 1.9% | 0.0% |
6 Months | 19.3% | 10.7% | 0.0% |
1 Year | 12.83% | 4.6% | -1.1% |
3 Years | -72.31% | 14.2% | -22.1% |
Market Capitalization | 3.1B |
Book Value | - $2.8 |
Earnings Per Share (EPS) | -1.62 |
PEG Ratio | 0.63 |
Wall Street Target Price | 10.33 |
Profit Margin | -6.76% |
Operating Margin TTM | 21.06% |
Return On Assets TTM | 3.82% |
Return On Equity TTM | -686.52% |
Revenue TTM | 8.8B |
Revenue Per Share TTM | 24.0 |
Quarterly Revenue Growth YOY | 9.8% |
Gross Profit TTM | 5.8B |
EBITDA | 2.9B |
Diluted Eps TTM | -1.62 |
Quarterly Earnings Growth YOY | 1.12 |
EPS Estimate Current Year | 3.93 |
EPS Estimate Next Year | 4.18 |
EPS Estimate Current Quarter | 1.02 |
EPS Estimate Next Quarter | 0.7 |
What analysts predicted
Upside of 21.82%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 8.4B | ↓ 3.94% |
Net Income | -4.1B | ↓ 272.55% |
Net Profit Margin | -49.5% | ↓ 77.06% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 8.6B | ↑ 2.64% |
Net Income | -1.8B | ↓ 57.02% |
Net Profit Margin | -20.73% | ↑ 28.77% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 8.0B | ↓ 6.67% |
Net Income | -559.0M | ↓ 68.65% |
Net Profit Margin | -6.96% | ↑ 13.77% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 8.4B | ↑ 5.07% |
Net Income | -937.0M | ↑ 67.62% |
Net Profit Margin | -11.11% | ↓ 4.15% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 8.1B | ↓ 3.68% |
Net Income | -212.0M | ↓ 77.37% |
Net Profit Margin | -2.61% | ↑ 8.5% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 8.8B | ↑ 7.79% |
Net Income | -592.0M | ↑ 179.25% |
Net Profit Margin | -6.76% | ↓ 4.15% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 2.0B | ↑ 4.02% |
Net Income | 399.0M | ↓ 387.05% |
Net Profit Margin | 19.5% | ↑ 26.57% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 2.2B | ↑ 7.18% |
Net Income | -410.0M | ↓ 202.76% |
Net Profit Margin | -18.7% | ↓ 38.2% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.9B | ↓ 11.35% |
Net Income | -209.0M | ↓ 49.02% |
Net Profit Margin | -10.75% | ↑ 7.95% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.2B | ↑ 11.47% |
Net Income | 26.0M | ↓ 112.44% |
Net Profit Margin | 1.2% | ↑ 11.95% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.2B | ↑ 3.28% |
Net Income | -378.0M | ↓ 1553.85% |
Net Profit Margin | -16.89% | ↓ 18.09% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.4B | ↑ 7.6% |
Net Income | 395.0M | ↓ 204.5% |
Net Profit Margin | 16.4% | ↑ 33.29% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 27.4B | ↓ 26.8% |
Total Liabilities | 24.6B | ↓ 21.93% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 33.9B | ↑ 23.38% |
Total Liabilities | 32.7B | ↑ 32.86% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 31.2B | ↓ 7.87% |
Total Liabilities | 30.6B | ↓ 6.52% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 29.2B | ↓ 6.4% |
Total Liabilities | 29.2B | ↓ 4.44% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 25.7B | ↓ 12.04% |
Total Liabilities | 25.4B | ↓ 13.03% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 27.4B | ↑ 6.48% |
Total Liabilities | 27.4B | ↑ 7.89% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 26.3B | ↓ 6.65% |
Total Liabilities | 25.9B | ↓ 7.35% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 25.7B | ↓ 2.33% |
Total Liabilities | 25.4B | ↓ 1.7% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 25.4B | ↓ 0.94% |
Total Liabilities | 25.3B | ↓ 0.5% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 33.8B | ↑ 32.82% |
Total Liabilities | 33.4B | ↑ 32.16% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 27.1B | ↓ 19.92% |
Total Liabilities | 27.3B | ↓ 18.36% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 27.4B | ↑ 1.06% |
Total Liabilities | 27.4B | ↑ 0.49% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.5B | ↓ 34.45% |
Investing Cash Flow | -196.0M | ↓ 106.79% |
Financing Cash Flow | -1.4B | ↓ 72.74% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.5B | ↑ 0.0% |
Investing Cash Flow | -419.0M | ↑ 113.78% |
Financing Cash Flow | 1.4B | ↓ 206.65% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.1B | ↓ 25.98% |
Investing Cash Flow | -261.0M | ↓ 37.71% |
Financing Cash Flow | -2.3B | ↓ 258.97% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.4B | ↑ 28.35% |
Investing Cash Flow | 409.0M | ↓ 256.7% |
Financing Cash Flow | -1.5B | ↓ 34.05% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -728.0M | ↓ 151.05% |
Investing Cash Flow | -303.0M | ↓ 174.08% |
Financing Cash Flow | -474.0M | ↓ 68.67% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -1.3B | ↓ 1126.83% |
Investing Cash Flow | -167.0M | ↑ 187.93% |
Financing Cash Flow | -36.0M | ↓ 94.29% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 475.0M | ↓ 137.61% |
Investing Cash Flow | -303.0M | ↑ 81.44% |
Financing Cash Flow | -276.0M | ↑ 666.67% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 154.0M | ↓ 67.58% |
Investing Cash Flow | -78.0M | ↓ 74.26% |
Financing Cash Flow | -142.0M | ↓ 48.55% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 268.8M | ↑ 74.53% |
Investing Cash Flow | -30.0M | ↓ 61.54% |
Financing Cash Flow | -155.1M | ↑ 9.25% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 282.0M | ↑ 4.92% |
Investing Cash Flow | -2.0B | ↑ 6556.67% |
Financing Cash Flow | 1.8B | ↓ 1270.59% |
Sell
Neutral
Buy
Bausch Health Companies Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Bausch Health Companies Inc | -10.02% | 19.3% | 12.83% | -72.31% | -62.93% |
Neurocrine Biosciences Inc. | -0.11% | 28.23% | 35.27% | 41.85% | 77.04% |
Haleon Plc Spon Ads | -0.24% | 1.82% | -5.93% | 13.5% | 13.5% |
Zoetis Inc. | -10.88% | -10.51% | -15.19% | -11.92% | 47.93% |
Viatris Inc. | -3.97% | 24.7% | 21.76% | -16.16% | -30.48% |
Catalent, Inc. | -0.66% | 31.9% | 24.68% | -51.57% | 26.05% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Bausch Health Companies Inc | 71.75 | NA | 0.63 | 3.93 | -6.87 | 0.04 | NA | -2.8 |
Neurocrine Biosciences Inc. | 53.44 | 53.44 | 0.44 | 4.78 | 0.13 | 0.09 | NA | 22.61 |
Haleon Plc Spon Ads | 29.86 | 29.86 | 1.69 | 0.45 | 0.07 | 0.04 | 0.03 | 1.8 |
Zoetis Inc. | 28.76 | 28.76 | 2.58 | 5.8 | 0.5 | 0.13 | 0.01 | 10.9 |
Viatris Inc. | 225.0 | 225.0 | NA | 2.78 | 0.0 | 0.03 | 0.04 | 17.05 |
Catalent, Inc. | 211.02 | NA | 2.06 | 0.48 | -0.3 | -0.01 | NA | 20.41 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Bausch Health Companies Inc | Buy | $3.1B | -62.93% | 71.75 | -6.76% |
Neurocrine Biosciences Inc. | Buy | $13.3B | 77.04% | 53.44 | 13.23% |
Haleon Plc Spon Ads | Buy | $38.2B | 13.5% | 29.86 | 9.28% |
Zoetis Inc. | Buy | $66.5B | 47.93% | 28.76 | 27.43% |
Viatris Inc. | Hold | $13.4B | -30.48% | 225.0 | 0.35% |
Catalent, Inc. | Hold | $10.1B | 26.05% | 211.02 | -31.77% |
ICAHN CARL C
Goldentree Asset Management LP
Paulson & Company Inc
Franklin Resources Inc
Nomura Holdings Inc
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND
bausch health companies inc. (nyse/tsx: bhc) is a global company that develops, manufactures and markets a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. we are delivering on our commitments as we build an innovative company dedicated to advancing global health. our approximately 22,000 employees are united around our mission of improving people’s lives with our health care products, and we manufacture and market health care products directly or indirectly in approximately 100 countries.five pillars, or guiding principles, represent the foundation on which we are realizing our mission as an organization: people, quality health care outcomes, customer focus, innovation and efficiency. more information can be found at www.bauschhealth.com.###
Organization | Bausch Health Companies Inc |
Employees | 20270 |
CEO | Mr. Thomas J. Appio |
Industry | Health Technology |
Marqeta, Inc.
$8.48
-0.59%
Endeavor Group Holdings, Inc.
$8.48
-0.59%
Global X Nasdaq 100 Covered Call Etf
$8.48
-0.59%
Grupo Aeroportuario Del Sureste, Sabdecv
$8.48
-0.59%
Middleby Corp.
$8.48
-0.59%
Dnp Select Income Closed Fund
$8.48
-0.59%
Masonite International Corp
$8.48
-0.59%
Zillow Group, Inc. - Class C Shares
$8.48
-0.59%
Tenet Healthcare Corp.
$8.48
-0.59%